FindMyKOL
Clinical trialNCT04387071TerminatedPhase 1/PHASE2Interventional

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

SponsorUniversity of Southern CaliforniaEnrollment2Locally Advanced Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8Unresectable Malignant Solid Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is packaged in a protein, known as a virus-like particle (VLP). VLPs are detected and processed by cells of the immune system. The DNA contained in CMP-001 activates the immune system and recruit cells of the immune system to the tumor. INCAGN01949 is an antibody, a type of protein, which has been shown to stimulate the immune system. Injecting CMP-001 and INCAGN01949 directly into the tumor may work against tumor cells to slow tumor growth by causing tumor cells to die.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Honorhealth Research Institute

    Scottsdale, Arizona, United States

  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • Hoag Memorial Hospital

    Newport Beach, California, United States

  • Lucile Packard Children'S Hospital Stanford University

    Palo Alto, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949VLP-encapsulated TLR9 Agonist CMP-001
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
29 Apr 2021
Primary completion
28 Dec 2022
Completion
28 Dec 2022
Last update posted
17 Apr 2026
Registered enrollment
2
Registry id
NCT04387071
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.